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METHODS, SYSTEMS, AND DEVICES FOR
TREATING TINNITUS WITH VNS PAIRING
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claims the benefit of U.S. Provisional
Patent Application No. 61/699,470, filed Sep. 11, 2012, U.S.
Provisional PatentApplication No. 61/614,369,filed Mar. 22,
2012, U.S. Provisional Patent Application No. 61/598,185,
filed Feb. 13, 2012, and U:S. Provisional Patent Application
No. 61/558,287,filed Nov. 10, 2011. This application is also
a Continuation-In-Part of U.S. patent application Ser. No.
13/095,570, filed Apr. 27, 2011, which claims the benefit of
US. Provisional Patent Application No. 61/328,621, filed
Apr. 27, 2010 and which is a Continuation-In-Part of U.S.
patent application Ser. No. 12/485,040, filed Jun. 15, 2009,
which claimsthe benefit of: U.S. Provisional Patent Applica-
tion No. 61/077,648, filed Jul. 2, 2008; U.S. Provisional
Patent Application No. 61/078,954,filed Jul. 8, 2008; U.S.
Provisional Patent Application No. 61/086,116,filed Aug. 4,
2008; and U.S. Provisional Patent Application No. 61/149,
387,filed Feb. 3, 2009. All of these applications are incorpo-
rated herein by reference as if reproducedin their entirety.
RELATED APPLICATIONS
The present application 1s a division ofapplication Ser. No.
13/673,764, filed Nov. 9, 2012, entitled METHODS, SYS-
TEMS, AND DEVICES FOR TREATING TINNITUS
WITH VNSPAIRING,the disclosure of which is hereby
incorporated by reference herein in its entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
Notapplicable.
REFERENCE TO A MICROFICHE APPENDIX
Notapplicable.
BACKGROUND
Tinnitus is characterized by an auditory sensation in the
absence of external sound. Approximately 12 million indi-
viduals in the United States have some degree of tinnitus.
About 5 million of these sufferers have severe tinnitus that
interferes with their daily activities and their quality oflife. In
fact, severe tinnitus can lead to depression and other mental
health challenges that severely affect the patient and the
patient’s family members. Therapies such as masking, sound
therapy, electrical stimulation, and drugs have shown some
benefit. Unfortunately, these treatments are non-specific and
are insufficient to reverse the brain changesthat cause tinni-
tus. Therefore, treatment of tinnitus remains a significant
unmet need.
Numeroustherapies have been usedto treat or alleviate the
symptomsoftinnitus. For example, pharmaceutical therapies
such as antidepressants, anti-anxiety medications, as well as
other medicinal compounds have been attempted. Neuro-
stimulation techniques including transcranial magnetic
stimulation and cortical stimulation have been usedto allevi-
ate symptoms. Sound has been used in several ways, includ-
ing masking therapy auditory exposure and frequency dis-
crimination training.
25
30
40
45
2
U.S. Patent Application Publication 2007/0027504 (Bar-
rett) describes a system fortreating tinnitus using vagus nerve
stimulation. A patient’s vagus nerve was stimulated as the
patient experienced tinnitus symptoms to temporarilyallevi-
ate the symptoms. No audible tonesare specifically presented
or paired in Barrett’s therapy.
USS. Pat. No. 6,990,377 (Gliner) describes a therapy to
treat visual impairments. The therapy includes presenting
various types of visual stimuli in conjunction with stimula-
tion ofthe visual cortex. The therapy described in Gliner does
not control the timing relationship of the stimuli and the
stimulation.
USS. Patent Application Publication 2007/1079534 (Firlik)
describes a therapy having patient interactive cortical stimu-
lation and/or drug therapy. The therapy has patients perform-
ing tasks, detecting patient characteristics, and modifying the
stimulation depending on the detected patient characteristics.
The therapy described in Firlik does not control the timing
relationship between the tasks and the cortical stimulation.
It is commonin the prior art to suggest that stimulation of
the cortex, the deep brain, the cranial nerves, and the periph-
eral nerves are somehow equivalent or interchangeable to
producetherapeutic effects. Despite these blanket statements,
stimulation at different parts of the nervous system is not
equivalent. It is generally understoodthat the vagus nerveis a
nerve that performs unique functions through the release of a
wide array ofneuromodulators throughout the brain. To gen-
erate certain kinds ofplasticity, the timing of the stimulation
ofthe vagus nerveis critical in producing specific therapeutic
effects.
USS. Pat. No. 6,104,956 (Naritoku) is representative of
work done using vagus nerve stimulation (VNS)to treat a
variety of disorders, including epilepsy, traumatic brain
injury, and memory impairment. The VNSis delivered with-
out any other therapy. To improve memory consolidation,
VNSis delivered several minutes after a learning experience.
Memory consolidation is unrelated to the present therapy for
treating tinnitus.
SUMMARY
For purposes of summarizing the disclosure, certain
aspects, advantages, and novel features ofthe disclosure have
been described herein.It is to be understood that not neces-
sarily all such advantages may be achieved in accordance
with any particular embodimentofthe disclosure. Thus, the
disclosure may be embodied or carried out in a mannerthat
achieves or optimizes one advantage or group of advantages
as taught herein without necessarily achieving other advan-
tages as may be taught or suggested herein.
In an embodiment the disclosure includes a method of
treating tinnitus comprising measuring a patient’s hearing,
determining the patient’s hearing loss andthe patient’ stinni-
tus frequency using the measurements ofthe patient’s hear-
ing, programming a clinical controller with the measure-
ments of the patient’s hearing, selecting a plurality of
therapeutic tones, where the therapeutic tones are selected to
be at least a half-octave above or below of the patient’s
tinnitus frequency, setting an appropriate volumefor each of
the plurality oftones, repetitively playing each ofthe plurality
of therapeutic tones, and pairing a vagus nerve stimulation
pulse train with each playing of a therapeutic tone, thereby
reducing the patient’s perception oftinnitus.
In another embodiment the disclosure includes a system
fortreating tinnitus comprising a clinical controller executing
tinnitus therapy software, a VNS implantable pulse generator
(PG) in communication with the clinical controller and
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receiving stimulation signals from the clinical controller, a
VNSlead connected to the VNS IPG, a VNSelectrode con-
nected to the VNS lead and receiving stimulation signals
through the VNSlead from the VNS IPG, and headphones
connectedto the clinical controller, wherein the clinical con-
troller plays selected sound files through the headphones
while sending stimulation signals to the VNS IPG such that
the soundfiles may be heard by a patient while a stimulation
pulse train at the VNS electrode causes the patient’s vagus
nerveto be stimulated.
In yet another embodiment the disclosure includes a
methodoftreating tinnitus comprising measuring a patient’s
hearing, determining the patient’s hearing loss and the
patient’s tinnitus frequency using the measurements of the
patient’s hearing, programminga clinical controller with the
measurementsofthe patient’s hearing, selecting a plurality of
therapeutic tones where the therapeutic tones are selected to
be at least a half-octave above or below of the patient’s
tinnitus frequency, generating sound files by shaping the
selected therapeutic tones using a ramp function, modulating
the soundfiles with phase information that simulates a sound
source location, setting an appropriate volumefor each ofthe
plurality oftones, repetitively playing each ofthe plurality of
therapeutic tones, and pairing a vagus nerve stimulation pulse
train with each playing ofa therapeutic tone, thereby reducing
the patient’s perception of tinnitus.
These andother features will be more clearly understood
from the following detailed description taken in conjunction
with the accompanying drawings and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
For a more complete understandingofthis disclosure, ref-
erence is now madeto the following brief description, taken
in connection with the accompanying drawings and detailed
description, wherein like reference numerals represent like
parts.
FIGS. 1A, 1B, and 1C are graphs depicting aspects of a
patient’s hearing;
FIG. 2 depicts a pure tone;
FIG. 3A depicts an up ramp tone;
FIG. 3B depicts a down ramp tone;
FIG.4 depicts location encoded sounds;
FIGS. 5A, 5B, and 5C are graphs of stimulation timing
relationships;
FIG. 6 depicts an implantable vagus nerve stimulation
system;
FIG.7 depicts a paired VNStinnitus therapy system;
FIG. 8 is a flowchart depicting a patient therapy initiation
routine;
FIG.9 is a flowchart depicting a tone selection routine;
FIG. 10 is a flowchart depicting a patient therapy routine;
FIG. 11 is a flowchart depicting a patient home therapy
routine;
FIG. 12 is a flowchart depicting a sound file generation
routine;
FIG.13 is a screen shot ofthe paired VNStinnitus therapy
software menu;
FIG. 14 is a screen shot of an audiogram input screen;
FIG. 15 is a screen shot of an audiogram input screen with
sample data input;
FIG.16 is a screen shot of interpolated audiogram data;
FIG. 17 is a screen shot of therapeutic tone selection;
FIG. 18 is a screen shot of therapeutic tone selection with
a tinnitus frequency notch;
FIG. 19 is a screen shot of therapeutic tone selection with
multiple tinnitus frequency notches;
10
30
40
45
50
65
4
FIG.20 is a screen shot of therapeutic tone selection with
twotinnitus frequency notches;
FIG.21 is ascreen shot oftherapeutic tone volumesetting;
FIG. 22 is a screen shot of therapeutic tone selection with
additional notches;
FIG. 23 is a screen shot of stimulation parametersetting;
and
FIG.24 is a screen shot of therapy delivery.
DETAILED DESCRIPTION
It should be understoodat the outset that although an illus-
trative implementation of one or more embodimentsare pro-
vided below, the disclosed systems and/or methods may be
implemented using any number of techniques, whether cur-
rently knownor in existence. The disclosure should in no way
be limited to the illustrative implementations, drawings, and
techniquesillustrated below, including the exemplary designs
and implementations illustrated and described herein, but
may be modified within the scope of the appended claims
along with their full scope of equivalents. The present appli-
cation describes several embodiments, and noneofthe state-
ments below should be taken as limiting the claims generally.
Where block diagrams have been used to illustrate the
embodiments,it should be recognized that the physical loca-
tion where described functions are performed are not neces-
sarily represented by the blocks. Part of a function may be
performed in one location while another part of the same
function is performed at a distinct location. Multiple func-
tions may be performedat the samelocation. In a functional
block diagram, a single line may represent a connection, in
general, or a communicable connection, particularly in the
presence of a double line, which may represent a power
connection.In either case, a connection maybe tangible, as in
a wire, or radiated, as in near-field communication. An arrow
may typically represent the direction of communication or
poweralthough should not be taken as limiting the direction
of connected flow.
Repeatedly pairing a range of non-tinnitus frequency
sounds withVNSreducesthe perception oftinnitus soundsin
a patient with tinnitus. No one ever before recognized that
playing repeatedVNSpaired sounds could reduce symptoms
of tinnitus.
A common causeof hearing loss that leads to tinnitus is
cochlear damage from noise trauma. Elevated synchronous
spontaneous activity in the central auditory system may
account for the tinnitus perceptthatarises following hearing
loss. As a result, some neurons in the auditory cortex no
longer receive their normal input. These neurons start
responding to adjacent frequencies, and therefore a popula-
tion of neurons starts firing spontaneously and synchro-
nously. This pathological activity is thought to give rise to the
tinnitus sensation. Based on these considerations, we devel-
oped an approachto reduce the tinnitus percept by redistrib-
uting the frequencies along the auditory tonotopic axis, thus
reducing the responsiveness of neurons that had too much
input. Our approach pairs selected tone presentations other
than the tinnitus frequency with simultaneous stimulation of
the vagus nerve to induce a redistribution of the distorted
auditory cortical frequency map observed in tinnitus. This
approach seems to alleviate the presumed behavioral and
neurophysiological correlations of tinnitus in a rat model of
the disease.
The mechanism of our therapy may be referred to as
repeated paired training. A repeatedpairedtraining is defined
as follows:
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A “training” may be definedas a discrete event in time that
hasa starting point and a stopping point. In the case oftinnitus
therapy, a training may be a brief sound, such as a tone witha
distinct frequency.
A training may be defined as “paired” when a discrete
vagus nerve stimulation pulse train, having a starting point
and a stopping point, occurs during a training. This requires
that the training andVNSstart and stop in a mannerthatlinks
the two together in time. When both the training and VNS
have stopped, there may follow a period whenthere is neither
training norVNS.This non-training period allowsthe brain to
perceive the next event as a separate discrete event. The
mechanism of therapy takes advantage of the fact that the
brain can distinguish between two discrete events close
together in time.
A “repeated paired training” maybe defined as a recurring
sequenceofpaired trainings. The mechanism ofour therapy
is the cumulative effect of repeated paired trainings.
The vagus nerve is composed ofsomatic andvisceralaffer-
ents (e.g., inward conducting nerve fibers which convey
impulses toward a nerve center such as the brain or spinal
cord) and efferents (e.g., outward conducting nerve fibers
which convey impulses to an effector to stimulate it and
produce activity). 80% of the fibers in the vagus nerve are
afferentfibers; the rest are efferent. The vast majority ofvagal
nerve fibers are C fibers, with the majority being visceral
afferents having cell bodies lying in masses or ganglia in the
skull. The central projections terminate largely in the nucleus
of the solitary tract which sendsfibers to various regions of
the brain (e.g., the hypothalamus, thalamus, locus ceruleus,
and amygdala); others continue to the medial reticular forma-
tion ofthe medulla, the cerebellum, the nucleus cuneatus, and
other regions. Afferents activate both ascending and descend-
ing pathways.
The vagus nerve may be contacted at any point along its
length or one of its branches. For instance, stimulating or
sensing electrodes may be located directly on, or close to, the
left and/or right vagus nerve(s) in a cervical location. Alter-
natively, the vagus nerve could be stimulated at a near-dia-
phragmatic location (e.g., supra-diaphragmatic or sub-dia-
phragmatic).
Stimulation of the vagus nerve may beneficially activate
one or more of the gustatory pathways, olfactory pathways,
pro-inflammatory or anti-inflammatory pathways, respira-
tory pathways, cardiac pathways, baroreceptor pathways, and
the somatosensory pathways, causing a response of neural
activity in variousareas ofthe brain. Vagus nerve stimulation
mayalso affect neurotransmitter pathways such as noradren-
ergic, serotoninergic, dopaminergic catecholaminergic,
GABAergic, opioidergic and cholinergic pathwayssimilarly.
Neural activating circuits may include the circuit of Papez,
the mesolimbic pathway, the mesocortical pathway or the
nigrostriatal pathway. The effect of such responsive effect on
the brain tissue may be excitatory or inhibitory and may
potentiate acute and/or long-term changes in neuronal activ-
ity.
The afferent vagus nerve feeds in the Nucleus Tractus
Solitarius which in turn feeds into several deep brain nuclei
including nucleusbasalis and locus ceruleus. Each activation
of the vagus nerve results in a release of acetylcholine from
the nucleus basalis and norepinephrine from the amygdala
and locus ceruleus. These neurotransmitters influence the
cortex and otherparts ofthe brain. The contextofthis release
of neuromodulators defines the effects.
Therelease of the neuromodulators resulting from activa-
tion of the vagus nerve during a paired sensory event gener-
ates plasticity in the cortex that is specific to the sensory
15
30
40
45
6
event. The pairing effectively tells the brain what to learn.
Activation of the vagus nerve during a sensory event such as
a sound or sound sequence generatesplasticity in the auditory
cortex that is specific to the sound or sound sequence because
the perception of the sound coincides with the release of
neuromodulators in the auditory cortex. Activation of the
vagus nerve during a motion generates specific plasticity in
the motor cortex, again because the action and released neu-
romodulators coincide in the motor cortex. The conjunction
ofthese simultaneousactivations generates specific plasticity
with a very briefwindow,less than eight secondsfortinnitus.
Until our experiments,the synergy ofthese activations was
unappreciated. Presenting a sensory event at the same time as
activation of the vagus nerve has an effect on the area ofthe
cortex related to the sensory event. Timing a sensory event
with vagusnerve stimulationactivates the appropriate parts of
the brain. The described tinnitus therapy has been developed
using these principles and tested clinically.
The tinnitus therapy includes a controlled-timing vagus
nerve stimulation. The vagus nerve may bestimulated using
effective methods, such as directelectrical stimulation. Direct
electrical stimulation of the vagus nerve may be performed
using an implantable vagus nerve stimulator or a percutane-
ous vagus nerve stimulator to provide electrical pulses to an
electrode close to the vagus nerve tissue. Other methods of
stimulating the vagus nerve could be used as appropriate, as
long as the timing of the vagus nerve stimulation can be
controlled.In accordance with an embodimentofthe therapy,
an implantable vagus nerve stimulation device may be
implanted in the patient. Alternatively, a percutaneous lead
could be attached to an electrode at the vagus nerve through
the patient’s skin to provide stimulation of the vagus nerve.
The necessary surgery may be performed in advance of the
actual therapy, so the tissue has timeto heal.
Whenthe therapy is ready to begin, the patient’s hearing
and tinnitus symptomsare assessed. An audiogram may be
generated by an audiologist to characterizethe patient’s hear-
ing loss. Tinnitus pitch matching may be done to measure one
or more frequencies at which the patient is experiencing
tinnitus. One patient’s hearing is depicted in FIG. 1A, and the
patient’s tinnitus symptomsis depicted in FIG. 1B. A range of
therapeutic tones for the patient is depicted in FIG. 1C.
Because the hearing and symptoms of every patient is indi-
vidual and unique, the hearing loss, tinnitus symptoms, and
range of therapeutic tones maydiffer from those shown.
Using the knowledgeofthe patient’s hearing loss and the
frequencyor frequencies that characterize a patient’s tinnitus
symptoms, the clinician selects a set of therapeutic tones at
frequencies the patient can hear, not including the patient’s
tinnitus frequencies. The clinician may select tones at fre-
quencies ranging from 170 hertz (Hz) to 16 kilohertz (kHz)
and adjust the intensity accordingly. In accordance with an
embodiment, 25 therapeutic frequencies may be selected.
The distribution of frequencies may be based on Melscales.
In accordance with an embodiment, therapeutic tones may
be generated using pure sine wave tones with a sampling rate
of 44,100 Hz. This relatively high sampling rate ensures the
tones are pure. The sampling rate should beat least twice as
high as the highest frequency being used as a tone.
Using the data generated by the audiogram, a set of sound
files may be generated for the therapy.A therapeutic tone may
bea pure tone, as shown in FIG.2. A pure tone maybe defined
as a presentation of a single frequency that exhibits no har-
monicdistortions. For the purposeofthis therapy, a tone may
be said to be pure whenthe ratio ofthe single frequency to any
other frequency (harmonics, ambient noise, etc.) is 20:1 or
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greater. A tone maybesufficiently pure when only the single
frequency can be discerned bya patient.
Because a pure tone as a sine wavehas an abruptstart and
stop, the presentation of a pure tone can seem to include
unpleasant pops at the beginning and end of the tone. To
prevent this phenomenon, a 4-10 millisecond ramp can be
introduced to modulate the start and stop. A ramp up, as
shown in FIG. 3A, may be usedatthestart of the tone and a
ramp down,as shown in FIG. 3B, may be used before the stop.
The brain may struggle when presented with a stereo in-
phase, equal amplitude pure tone, becausethe lack oflocation
information in this simple tone makes it impossible for the
mindto place the source of the sound in space. To make the
tone presentation more natural, to give the sound an apparent
location in space both in terms of direction and distance, the
therapy may include phase and amplitude adjustments
betweenthe left and right headphonespeakers, so that a tone
is heard by the patient as existing at a specific location in
space.
Encoding multiple locations which are applied randomly
to the tones may be important, becausetraining an association
between a specific tone and a specific location may have
adverse consequences. We do not wantto train the patient to
pay attention to only one location or tone, but rather have the
VNSoccur at random locations and frequencies.
A variety of models can be used to encode locations and
environments. In accordance with one embodiment, a rectan-
gular room, with a drop ceiling, carpet, four walls, and micro-
phonesatspecific locations provides the model environment.
The model environment simulates the echoes, delays, and
absorption at the microphone. Output is determined at seven-
teen locations in each of the two rooms. A second environ-
ment may be one whereall walls completely absorb sound,
whichis effectively the same as being outdoors.
For the 34 locations in the two rooms, a set of impulse
functions is generated. Each of these impulse functions is
multiplied with a sine wave of a selected frequency to create
a complex tone waveform for that location, distance, room,
and tone, as shown in FIG. 4. To create the sense of a tone
coming from a specific location in space, the sound for the
right ear is given an intensity I, and the soundfor the left ear
is given an intensity I, and the left and right sounds are
separated with a time delay (). By changing the intensity
values andthe time delay, the sounds will seem to be coming
from different locations in space, in different environments.
The clinician may test the volumesetting of the device
before the therapy begins. The volumeofthe tones should be
audible and comfortable to the patient. Because a pure tone
necessarily has a louder output than a complex tone wave-
form, pure tones may be used to check the volumesettings.
In accordance with an embodiment, each of the 36 (334
locations+right andleft pure tones) complex tone waveforms
are multiplied with each of the 25 selected therapeutic tones
to provide 900 left and right sound files. These soundfiles
maybestored onthe clinical controller. The clinical control-
ler includes a soundcard connected to stereo headphones.
Whenthe clinical controller plays a soundfile, the soundcard
converts the sound file to an output that is received by the
stereo headphonesand converted to audible sound. Because
each soundcard and headphone has a unique frequency
response, they may introduce variables that may need to be
compensated. Typically, the therapy is conducted at 80 deci-
bels (dB) or less. Headphones and soundcards mayintroduce
harmonics and distortions volumes higher than 80 dB. A
patient may need to be able to hear a reasonable number(at
least two) of tones at 80 dB.
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The tinnitus therapy may be summarized as follows: The
patient has an implantable VNS device implanted so that it
can provide stimulation to the patient’s vagus nerve on com-
mand. An audiologist generates an audiogram forthepatient.
The tinnitus frequency or frequencies are determined. The
frequency ofeach therapeutic soundortone is selected by the
audiologist or clinician based on the tinnitus frequency. The
apparent location of each tone is established by the audiolo-
gist, clinician, or an automated process that provides a suit-
able selection of perceived tone locations. The tone may be
shaped by aramp. The clinician goes through asoftwaresetup
procedure, and a clinical setup is performed.
The intensity of each therapeutic tone is set. Typically the
intensity is assigned an initial value. A clinician may check
with the patient to determine ifthe initial intensity settings are
appropriate and may changethe intensity ofone or more tones
accordingly. The intensity may be calculated from the audio-
gram data. Feedback loops maybe incorporated for automatic
control ofintensity. From theintensity, the voltage required to
producethe tone is determined. Typicallythis is performed by
software, automatically.
An audiogram is generated by an audiologist and provided
as input to the software. The audiogram measuresthe hearing
loss at each frequency, measured in dB Hearing Loss (HL).
The data from the audiogram is then converted from a hearing
loss measure into dB Sound Pressure Level (SPL). A sound
check may be performed. Thetinnitus therapy, once set up by
the clinician, may be performed bythe patient at home. The
software may give options to the clinician to set-up the
therapy for home use, in particular to allow the patient to
deliver the therapy to themself, at home, while not allowing
the patient to change the parameters of the therapy.
The software is designed to deliver the therapeutic tones
and the vagus nerve stimulation to the patient at the same
time. In accordance with an embodiment, the therapeutic
tones are each about 500 milliseconds in duration and the
vagus nervestimulation pulse train is about 500 milliseconds.
In accordance with an embodiment, a therapy session may
include about 300 therapeutic tones paired with about 300
vagus nerve stimulations. In accordance with an embodiment,
a therapy regime may include about six weeks of therapy
sessions, provided about five times per week. The tinnitus
therapy includes a numberofvariables that may be changed,
as appropriate.
In accordance with an embodiment, the therapeutic tones
are about 500 milliseconds. The duration of the therapeutic
tones may be made longer or shorter. FIG. 5A depicts a
relative timing diagram for the tone and vagus nerve stimu-
lation pulse train. FIG. 5B depicts a relative timing diagram
for a plurality of tones and vagus nerve stimulation pulse
trains. FIG. 5C depicts a relative timing diagram for randomly
spaced tones and vagusnerve stimulation pulse trains.
In accordance with an embodiment, twenty-five therapeu-
tic tones are selected by the clinician. The twenty-five tones
maybeselected at regular intervals through frequencies that
can be heard bythe patient, except the frequencies that char-
acterize the patient’s tinnitus or within a half-octave of the
tinnitus frequencies. More or less tones may be selected as
appropriate. The vagus nerve stimulation pulse trains deliv-
ered to the patient are 500 milliseconds in duration. The
duration of the vagus nerve stimulation pulse trains may be
longeror shorter as appropriate. The vagus nerve stimulation
pulse trains delivered to the patient are about 0.8 milliamps.
Theintensity of the stimulation may be moreorless than 0.8
milliamps, as appropriate. The intensity of the tones being
delivered to the patient should be set to a level that is com-
fortable for the patient. Depending on a patient’s hearing loss,
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the intensity of the tones may beset to a normallevel or a
higher level. In accordance with an embodiment, the thera-
peutic tones and vagus nerve stimulationsare delivered at the
sametime, within a few milliseconds. It may be appropriate to
begin the therapeutic tonesearlier than the vagus nerve stimu-
lation or after the vagus nerve stimulation. The tones are
typically delivered at 30-secondintervals. The intervals may
be changedas appropriate. The clinician mayselect 25 thera-
peutic tones. More or less tones maybe selected, as appro-
priate. The session will typically include 300 therapeutic
tones paired with vagusnerve stimulations. More orless tones
may be delivered during a session, as appropriate. The
therapy may include 20 sessions. More or less sessions may
be given, as appropriate. The sessions may be provided daily.
Sessions may be provided moreorless often, as appropriate.
By controlling the phase of the tones in a stereo environ-
ment, the tones may be giventhe subjective attribute ofappar-
ent location. The locations of one or more tones may be
varied, as appropriate. In accordance with an embodiment,
various randomizations may be introduced. The selection of
tones, from the therapeutic tones, for delivery to the patient,
may be randomized. The timing of the tone delivery may be
randomized. In accordance with an embodiment, the tones
have a 50% chanceofbeing delivered at 15 secondsintervals,
so that on average, the tones are delivered thirty seconds
apart. By controlling the phase of the tones in a stereo envi-
ronment, the tones may be given the subjective attribute of
apparentlocation. This location oftones may be randomized.
Avariety ofsystems and devices may be used to implement
the tinnitus therapy. A percutaneous lead may be used to
stimulate the vagus nerve. Becauseofthe risk of infection is
increased with a percutaneous lead, the duration of the
therapy delivered will necessarily be shorter (less than six
weeks) than is possible with an implanted lead.
As shownin FIG.6, an implant system 100 may include an
electrode 130, typically a cuff electrode. The electrode 130 is
connected by a lead 120 to an implantable pulse generator
(IPG) 110. The electrode 130 providesthe electrical stimula-
tion pulsetrain in close proximity to the vagusnerve. The lead
120 conveysthe electrical current to stimulate the vagus nerve
from the IPG 110 to the electrode 130. The IPG 110 includes
internal software to recetve commandsfrom a clinical con-
troller 140 as well as providing safety features. An example of
a transcutaneouselectrical stimulation system that could be
adaptedforuse in the described therapy may be found in U.S.
Pat. No. 7,797,042. Stimulation of the vagus nerve may be
doneat other sites along the vagus nerve and branchesofthe
vagus nerve.
The clinical controller 140 is connected to the IPG 110 by
radio frequency communication using a program interface
160. The Programming Interface (PI) 160 has a cable with a
universal serial bus (USB) connectorthat plugsinto the clini-
cal controller 140 and converts the information from the
clinical controller 140 into a radio frequency (RF) signal that
is transmitted to the IPG 110. The PI 160 converts the digital
signals from the computer and software into RF signals that
can be transmitted through the air and skin to the device and
receives RF signals back from the IPG 110. The IPG 110 then
translates the signal and acts on the commandsgivenit from
the clinical controller 140. The PI 160 may have a cable of at
least 6 feet long and may communicate with the IPG 110 at up
to 2 meters from the PI 160. The PI 160 is powered via the
USBconnection and does not require any additional power
source, such asbattery, or additional power connection. Other
communication methods could be implemented as appropri-
ate.
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As shownin FIG.7, the external controller 140, or clinical
controller, is typically a laptop computer running appropriate
software. The clinical controller 140 is communicably con-
nected to headphones 150 that are worn by the patient. Simi-
lar automated systemsare described in U.S. Pat. Nos. 6,155,
971 and 7,024,398, which are incorporated herein by
reference.
FIG.8 depicts a flow chart of the patient initialization and
therapy process. An audiogram is generated by an audiologist
at 202. The patient’s hearing loss and tinnitus frequencies are
identified at 204. Therapeutic tones are selected at 206. The
tones are shapedat 208. The tones are encoded with locations
at 210. The soundfiles are saved at 212. The intensity of each
tone is set and checked at 214. The therapy parameters are
programmed at 216. Therapy begins at 218.
Whenthe therapy is delivered, a tone selection process as
shown in FIG. 9 is used. A random toneis selected at 220. A
random location is selected at 222. A playtime is determined
at 224. The stimulation processis initiated at 226 so that the
tone is played and the vagus nerve is stimulated at the same
tine at 228. An end-therapy decision is made at 230. If the
therapy continues, a new random tone is selected at 220.
Otherwise, the therapy endsat 232.
The therapy is outlined in FIG. 10. The clinician logs into
the software at 234. A hardware check is performed at 236. A
patient set up is performed at 238. An audiogram is input at
240. Therapeutic tones are selected at 242. The intensity of
the tones is set at 244. The stimulation parameters are set at
246. The session parameters are set at 248. The therapy is
delivered at 250. The therapy data is saved at 252.
A patient hometherapy process is outlined in FIG. 11. A
patient logs into the software at 254. A hardware check is
performedat 256. The therapy begins at 258. The therapy data
is saved at 260.
A tone preparation process is shown in FIG. 12. A thera-
peutic tone is selected at 254. Each tone is encoded with
locationfiles at 256. The tone soundfiles are saved at 258. The
tone intensity is set at 260.
Specialized software has been developed to implementthe
tinnitus therapy. There are two modes in this software: At
Homeand Physician modes. The only modeavailable unless
the Physician Login has been accessed and the appropriate
password input is the At Home mode.In this mode only the
Deliver Tinnitus Therapy option is enabled. The At Home
modeallowspatients to initiate a therapy session—thisis the
only function allowedby this mode.In order to access the rest
ofthe program, the Physician Login button mustbe selected.
This allows the Physician to type in a password which allows
access to the rest of the software.
To login and access all other TAPS screens,the audiologist
or physician presses the Physician Login button (upperright
menubar, 4th button from the right—innermost button) and
enters the password. This opens full access to the software
and allowsall settings to be established and modified. At this
point the program is “unlocked”andall menusin the program
are available, as shown in FIG. 13. Thefirst option, Audio-
gram, is used by the physician/audiologist to enter the audio-
gram data. The second option, Therapy Tones Settings, is
used by the physician/audiologist to set the tones. The third
option, Program Implant, is used to set the stimulation set-
tings and allows impedance checks. The fourth option,
Deliver Tinnitus Therapy, is used only during clinicaltrials. It
allows the physician or audiologist to set a sham-control
group that does not receive paired VNS,but instead receives
tones-only or VNS-only (in sequences such that the patient
receives tones and VNS, but they are not received simulta-
neously). This allows blinding to be maintainedin a parallel
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study design. The “Log Patient File” option allows a patient’s
file to be saved. The “VNS”option allows independentdeliv-
ery ofVNS.
In order for therapy to be delivered, the tones and stimula-
tion must be set by the audiologist, physician, or healthcare
worker. The tones must beset first. To set the tones, the
Audiogram and the Therapy Tone Settings tabs must be com-
pleted. The Audiogram is accessed as shown in FIGS. 14-22.
FIG. 14 is the screen where Audiogram information is
added andinterpolated. The information may be loaded from
a file that was previously generated in by the specialized
software or entered manually. Once the audiogram is entered,
it can be saved to a file. In order to manually enter the data, the
audiologist or physician clicks in the appropriate cells of the
Audiogram Parameters table and types the values in as
needed for frequency and hearing loss of both the Left and
Right ears, as shown in FIG. 15. The user mustinterpolate the
audiogram in order to be able to access Therapy Tone Settings
and continue with therapy set up. In order to interpolate the
data into the Therapy Tone Settings, following the successful
entry of all audiogram parameters, the Interpolate button
must be selected, as shown in FIG. 16. The interpolated data
populates the Therapy Tone Parameters table on the Therapy
Tone Settings automatically. This data will not be saved until
either the Save to file . . . button or the Download button is
selected. The Savetofile . . . function prompts theuser to save
the file in a preferred location (an external USB drive is
recommended), and the Download function saves the data
into the IPG.In order to deliver propertherapy, the Download
function must be performedso that the therapy information is
loaded into the IPG’s memory.
As shownin FIG.17, after the Audiogram parameters are
populated with Audiogram-based data (either manually or
from afile) andsubsequently interpolated, the “Therapy Tone
Settings” button can be selected. The Tinnitus Frequencies
can now be added. This is also where the manualtesting ofthe
tones occurs and can be adjusted. Frequencies can be dese-
lected in order to notch out frequencies around the Tinnitus
frequency or frequencies.
For example, as shown in FIG.18, if a patient has tinnitus
in the left ear, around frequency of 1,100 Hz, the audiologist
is recommended to notch out tones being played in a 4
Octave around 1,100 Hz. To dothis, the frequency of 1,100 is
input into the drop down menu under Left and Tinnitus Fre-
quency as shownbelow(right middle of screen, FIG. 18). The
software will then automatically select the frequencies of
910, 1121, and 1360 Hz. If necessary, the audiologist or
physician can manually modify this by clicking on a fre-
quencyandselecting or deselecting the frequency.
As shown in FIG. 19, if the patient also has a tinnitus
frequency of 3500 in the right ear, the audiologist would add
“3500”in the Right—Tinnitus Frequency box, andthe soft-
ware will again automatically “notch out” frequencies
octave around 3,500 Hz. Note that the +box next to the tinni-
tus frequency can be clicked, and additional tinnitus frequen-
cies can be added.
As shown in FIG. 20, two tinnitus frequencies (1,100 Hz
and 3,500 Hz) are shown, and any frequency within a 4
octave of those frequencies are notched out (inactive fre-
quency buttons are grayed), so that the tinnitus frequencies
cannotbeselected.
As shownin FIG.21, the tone volumefor the sound level
that each tone is played at for each frequencyis also available
for input. The volumeplayed in the left and right ear is
adjustable—inthe example below,it is 170 Hz. Frequency is
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being adjusted to 100 dB for both theleft and right ears. The
Play Left or Play Right button can be selected to test the tones
and volumelevels.
FIG. 22 shows an additional three frequencies being
notched-out (7278, 8324, and 9506 Hz), as indicated by the
gray deselected buttons near the bottom ofthe screen.
The Program Implant menu, as shown in FIG. 23, allows
the user to set theVNS Parameters, check the lead impedance,
and then test and ultimately program the parameters into the
IPG.For each ofthe settings (Magnet, Train Duration, Ampli-
tude, Train Period, Frequency, Train Probability, Pulse Width,
Tone Time and Therapy Duration), the box next to thesetting
is clicked, and all available parameters are shown in a drop
down box. The appropriate valueis selected for each param-
eter. After all of the parameters are set, the user may Test or
Program the displayed parameters. It is recommended the
user verify that the VNS settings chosenare tolerable for the
patient. Selecting the Test button delivers a single train of
stimulation per the parameters displayed in the Parameters
menufor this purpose. This does not permanently program
the IPG, but only performs a one-timestimulation.
Once the useris satisfied that the chosen parameters are
appropriate and tolerable, the Program button must be
selected in order to program the IPG with the therapy param-
eters displayed in the Parameters menu. The values pro-
grammedvia the Program function are input into the IPG and
all subsequent therapy sessions will be performed at these
parameters. The user can modify the parameters at any time
by selecting new parameters and programming them into the
IPG.The user may also wantto verify the lead impedance.In
the Status portion of the Program Implant menu the lead
impedance can be checked by selecting a Check button.
Doing so delivers a small current pulse through the lead to
calculate the lead impedance. The user shall ensure that the
lead impedance check does not cause discomfort in the
patient. After the check button is selected, the lead impedance
value is shown. For any value above 10,000 ohms, a Warning
screen above remindsthe patient to contact their physician or
audiologist to see if any action needsto be taken.
As shownin FIG.24, the therapy is delivered by selecting
the PLAYbutton. For hometherapy, the patient may be given
limited access to some features in the specialized software.
The patient can administer therapy to themselves, and all the
data correspondingto the session will be recorded for subse-
quentreview by the clinician. Headphoneshave been selected
to deliver consistent tone intensity across the full range of
frequencies. Clinical and pre-clinical data has been collected
to support the effectiveness of the formatting.
The peripheral nervous system, central nervous system
including the brain and spinal cord can all be used as stimu-
lation locations. The choice of stimulation location largely
determines the behavioral and neurophysiologic outcome.
Even though similar neural populationsare activated by input
from two different locations, the manner in which they are
activated, for example, the pattern of activity generated
within the neuron population will depend on the time course
of activation, release of one or more neuromodulators, atten-
tion state, etc.
The neurophysiological consequencestherefore are bound
to be different. Given the large (and unknown) number of
variables that can influence the activation of a given neural
population, the mechanisms are likely to be complex and
unpredictable. There is no calculus to determine which loca-
tions will produce which effects. Finding a location that pro-
duces a given effect can only be done experimentally.It is not
valid to suggest that stimulation at one location makes it
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obvious to stimulate at a different location, evenifthe goal is
to stimulate the same population of neurons.
The same canbe said for stimulation parameters. Ata given
stimulation location, stimulation according to one set of
parameters will not necessarily produce the same(or similar)
effects as a stimulation according to another set of param-
eters. The frequency of stimulation, the current amplitude of
stimulation, the duration ofeach stimulation, the waveform of
stimulation, as well as other stimulation parameters can
changethe results of stimulation.
Our experiments have shown that the effect generated by
VNSpairing is very short, less than 15 seconds.A first tone at
a first frequency whenpaired withVNSgenerated an increase
in the numberofneuronsthat respondto the paired frequency.
A second unpaired tone at a second frequency, played 15
seconds after the paired VNSdid not show a corresponding
increase in the numberofneuronsthat respond to the second
frequency. Nothing in the prior art indicates this kind of
precise timing requirement.
Similarly, we have performed experiments in which mul-
tiple tones at a given frequency were paired with VNS and
given 30 seconds apart. This was donein the tinnitus study
(Engineeret al., 2011) in whichVNSwaspaired with each of
the randomly interleaved tones every 30 seconds (e.g., 1.3
kHz+VNS,thenwait for 30 seconds, then give 6.3 KHz+VNS,
then wait for 30 seconds, and so on). The tones were selected
such that they surrounded the tinnitus frequency and the
tinnitus frequencyitselfwas excluded. The idea wasto shrink
the representation ofthe tinnitus frequency thereby restoring
the map and synchronousactivity back to normal. When the
same tones were presented 8 secondsapart, the effect was less
thanifthe tones were presented 30 seconds apart, which was
surprising.
To cite another example, we have performed a series of
experiments where a tone is repeatedly paired with a foot-
shockto establish a conditioned fear response. Subsequently,
when the tone was presented without a foot-shock, the rat
would freeze, anticipating a foot shock. If the tone, without
the foot-shock, is then presented repeatedly, the fear caused
by the tone would eventually be extinguished, undoing the
conditioning. By pairing the tone (without the foot-shock)
withVNS,the fear is extinguished much more quickly. How-
ever, presenting the tone by itself and then giving VNS min-
uteslater, the fear is extinguished at the normal rate. These
results demonstrate that the precise timing betweenVNS and
the event, as well as the interval separating the VNS-event
pairings appear, to be important for inducing highly specific
plasticity.”
Neurostimulation does not behave in apredictable fashion.
Different stimulation locations produce different results,
even when both locations are cranial nerves. For example,
synchronization in the cerebral cortex is a manifestation of
epilepsy. Stimulating the vagus nerve causes desynchroniza-
tion of the cortex neurons, which has been proposed as a
potential mechanism for how vagusstimulation prevents an
epileptic seizure. Stimulation ofthe trigeminal nerve, another
cranial nerve, causes desynchronization as well. To determine
whetherthe plasticity induced byVNSis specific to the vagus
nerve, we paired stimulationofthe trigeminal nerve with a 19
kHz tone. However, when wepaired trigeminal stimulation
with a tone, in the same way wepaired VNSwith a tone, we
did not observe anyplasticity that was specific to the paired
tone. Pairing the trigeminal stimulation with a tone at a given
frequency did not changethe response to that frequency even
though it caused desynchronization as in the previous study.
Each stimulation location is unique across the full range of
effects. It appears that VNS may be uniquely suited to direct
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cortical plasticity and suggests that the vagus nerveis likely a
key conduit by which the autonomic nervous system informs
the central nervous system of important stimuli.
The VNSpairing therapy is more than the sum ofits con-
stituent parts. Simply playing a tone at a given frequency,
without VNS,does not result in a change in response to the
frequency. Similarly, VNS by itself did not produce any
changes in response to any frequency. Only by precisely
pairing VNS with a tone at a given frequency induces a
change in responseto the frequency.
Both VNSpairing and nucleus basalis stimulation (NBS)
pairing have been shown to change the numberof neurons
respondingto a paired frequency. To be effective, the current
amplitude parameter of the stimulation for VNS pairing is
more than twice the current amplitude used for NBSpairing.
There is an important difference between the neuromodula-
tors released by NBSfrom those released by VNS,so signifi-
cant differences between the results of NBS and VNSare
expected.
Another experiment demonstrated that pairing a single
tone at a specified frequency with VNSincreased the number
ofneurons responding notonly to that frequency but to close
frequencies, e.g., increased the bandwidth comparedto con-
trol rats. For NBSpairing, the bandwidth was not signifi-
cantly different from control rats. Unlike VNS pairing, NBS
pairing is highly invasive and may be unsuitable to provide a
practical therapeutic benefit. Similar results in one circum-
stance cannotbe extendedto predict similar results in another,
even slightly different, circumstance. Different stimulation
parameters have to be used for effective VNS pairing and
NBSpairing.
We observed that 30 seconds of VNS at 30 Hz and 0.8
milliamps (mA)transiently decreased the blood oxygensatu-
ration level (SpO,) in 3 rats. The standard 0.5 second VNS
used in this study had no measurable effect on either heart rate
or oxygen saturation (data not shown). Theseresults are con-
sistent with visual observations that brief VNS causes no
noticeable behavioral response. For example, rats did notstop
grooming or awaken whenbriefVNS wasdelivered.
Our observations that briefVNS (1) caused no behavioral
response, (2) caused no changeinheart rate, and (3) caused no
change in blood oxygensaturation, suggest thatVNS induced
plasticity is not equivalent to pairing tones with a painful or
irritating stimulus(as in footshockorair puff).
Three weeks after the end of therapy, neural recordings
were obtained from 13 of the 18 noise exposed rats. We
continued to follow 4 rats (2 therapy and 2 sham rats) for an
additional two months. Consistent with previous reports, the
untreated rats continued to exhibit impaired gap detection 3.5
monthsafter the noise exposure. Signs of impairment of gap
detection did not return in either ofthe rats that received the
VNS-multiple tone therapy. These results confirm that the
VNS-multiple tone therapy causes a long lasting reversal of
noise induced perceptual hearing abnormalitiesin rats.
In an effort to document changesin cortical synchroniza-
tion in unanesthetized rats, we looked for systematic effects
of VNS-multiple tone pairing on Electroencephalography
(EEG) in noise exposed rats (7 VNS paired and 4 VNSalone
rats). Although the data is variable because the animal’s
behavioral state was uncontrolled and the EEG electrode was
located at the vertex and not over auditory cortex, we never-
theless observedstatistically more gamma powerrelative to
alpha in treated rats comparedto untreated rats during the last
week oftherapy (p<0.05), but no difference between the EEG
of therapy and VNSalonerats during the first week. These
results are consistent with animalstudies that tinnitus can be
associated with abnormalcortical synchronization andclini-
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cal reports ofreduced alpha and increased gammain tinnitus
patients. As in our anesthetized recordings, the degree ofEEG
change wasnotsignificantly correlated with gap impairment
in individualrats.
Thepairing asit relates to tinnitusis notably unique. We are
not pairing just random sounds. We are not doing some kind
of auditory training or improving perception of one sound
over another. The key is that we are deliberately pairing the
non-tinnitus frequency. The reason is that pairing the non-
tinnitus frequencyresults in a decrease in the area ofthe brain
responding to the tinnitus frequency and decrease the syn-
chronousfiring of neurons. By reducing the response to the
tinnitus frequency and decreasing synchrony, weare able to
reduce tinnitus symptoms. Noonehas before shownthat the
symptomsoftinnitus can be improved by excluding specific
sounds and including specific sounds. A drug cannot work
selectively in this way, nor can cortical stimulation. VNS has
the specificity to do this.
Noneofthe description in the present application should be
read as implying that any particular element, step, or function
is an essential element that must be included in the claim
scope: the scope ofpatented subject matter is defined only by
the allowed claims. Moreover, none of these claims is
intended to invoke paragraph six of 35 USC section 112
unless the exact words “means for” are followed by a parti-
ciple. The claimsas filed are intended to be as comprehensive
as possible, and no subject matter is intentionally relin-
quished, dedicated, or abandoned.
At least one embodimentis disclosed and variations, com-
binations, and/or modifications of the embodiment(s) and/or
features ofthe embodiment(s) madeby a person having ordi-
nary skill in the art are within the scope of the disclosure.
Alternative embodiments that result from combining, inte-
grating, and/or omitting features of the embodiment(s) are
also within the scope of the disclosure. Where numerical
rangesor limitations are expressly stated, such express ranges
or limitations should be understoodto includeiterative ranges
or limitations of like magnitude falling within the expressly
stated ranges or limitations (e.g., from about 1 to about 10
includes, 2, 5, 4, etc.; greater than 0.10 includes 0.11, 0.12,
0.15, etc.). For example, whenever a numerical range with a
lower limit, R,, and an upper limit, R,, is disclosed, any
numberfalling within the range is specifically disclosed. In
particular, the following numbers within the range are spe-
cifically disclosed: R=R,+k*(R,-R,), wherein k is a variable
ranging from 1 percent to 100 percent with a 1 percent incre-
ment, i.e., k is 1 percent, 2 percent, 5 percent, 4 percent, 5
percent, ... , 50 percent, 51 percent, 52 percent, ..., 75
percent, 76 percent, 77 percent, 78 percent, 77 percent, or 100
percent. Moreover, any numerical range defined by two R
numbersas defined in the aboveis also specifically disclosed.
The use of the term “about” means+10 percentof the subse-
quent number unless otherwise defined. Use of the term
“optionally” with respect to any element ofa claim meansthat
the elementis required, or alternatively, the element is not
required, both alternatives being within the scope of the
claim. Use ofbroader terms such as comprises, includes, and
having should be understoodto provide support for narrower
terms such as consisting of, consisting essentially of, and
comprised substantially of. Accordingly, the scope ofprotec-
tion is not limited by the description set out above butis
defined by the claims that follow, that scope including all
equivalents ofthe subject matter ofthe claims. Each and every
claim is incorporated as further disclosure into the specifica-
tion and the claims are embodiment(s) of the present disclo-
sure. The discussion of a reference in the disclosureis not an
admissionthatit is prior art, especially any reference that has
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a publication date after the priority date of this application.
The disclosure ofall patents, patent applications, and publi-
cations cited in the disclosure are hereby incorporated by
reference, to the extent that they provide exemplary, proce-
dural, or other details supplementary to the disclosure.
While several embodiments have been provided in the
present disclosure, it should be understoodthat the disclosed
systems and methods might be embodied in many other spe-
cific forms without departing from the spirit or scope of the
present disclosure. The present examples are to be considered
as illustrative and notrestrictive, and the intention is not to be
limited to the details given herein. For example, the various
elements or components may be combined or integrated in
another system or certain features may be omitted, or not
implemented.
In addition, techniques, systems, subsystems, and methods
described andillustrated in the various embodiments as dis-
crete or separate may be combinedor integrated with other
systems, modules, techniques, or methods without departing
from the scope ofthe present disclosure. Other items shown
or discussed as coupledordirectly coupled or communicating
with each other may beindirectly coupled or communicating
through someinterface, device, or intermediate component
whether electrically, mechanically, or otherwise. Other
examples of changes, substitutions, and alterations are ascer-
tainable by oneskilled in the art and could be made without
departing from the spirit and scope disclosed herein.
Whatis claimedis:
1. A system for treating tinnitus comprising:
a clinical controller executing tinnitus therapy software;
a vagus nerve stimulation (VNS) implantable pulse gen-
erator (IPG) in communication with theclinical control-
ler and receiving stimulation signals from the clinical
controller;
a VNSlead connected to the VNS IPG;
a VNSelectrode connected to the VNSlead andreceiving
stimulation signals through the VNSlead from the VNS
IPG; and
a sound generator connected to the clinical controller,
whereinthe clinical controller plays selected soundfiles
through the sound generator while sending stimulation
signals to the VNS IPG such that respective selected
sounds of respective selected soundfiles may be heard
by a patient while a stimulation pulse train at the VNS
electrode causes the patient’s vagus nerve to be stimu-
lated, wherein
the system is configured to receive input based on the
patient’s tinnitus frequency, and
the selected soundsare therapeutic tones, and the system is
configured to automatically play the therapeutic tones
such that they are at least a half-octave above the
patient’s tinnitus frequency.
2. The system of claim 1, wherein the clinical controller is
a laptop computer.
3. The system of claim 1, wherein the VNS IPGreceives
stimulation parameters from the clinical controller.
4. The system of claim 1, wherein the selected sounds are
therapeutic tones, and wherein the system is configured to
execute a session that automatically applies at least 100 thera-
peutic tones per day.
5. The system of claim 1, wherein the selected sounds are
therapeutic tones, and wherein the system is configured to
execute a session that automatically applies at least 300 thera-
peutic tones per day.
6. The system of claim 1, wherein the selected soundsare
therapeutic tones, and wherein the system is configured to
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play each therapeutic tone such that each therapeutic tone has
a duration of about 500 milliseconds.
7. The system of claim 1, wherein the selected soundsare
therapeutic tones, and wherein the system is configured to
execute a session that repetitively plays each of the plurality
of therapeutic tones in a temporally random manner.
8. The system of claim 1, wherein the selected soundsare
therapeutic tones, and wherein the system is configured to
execute a session that repetitively plays each of the plurality
of therapeutic tones in a frequency-based random manner.
9. The system of claim 1, wherein the selected soundsare
therapeutic tones, and wherein the system is configured to
execute a session that plays each therapeutic tone such thatit
is a pure tone.
10. The system ofclaim 1, wherein the selected sounds are
therapeutic tones, and wherein the system is configured to
shape the therapeutic tones with a ramp function.
11. The system ofclaim 1, wherein the selected sounds are
therapeutic tones, and wherein the system is configured to
encode the therapeutic tones with location data.
12. The system ofclaim 1, wherein the selected sounds are
therapeutic tones, and wherein the system is configured to
automatically play the therapeutic tones such that they are at
least a half-octave below the patient’s tinnitus frequency.
13. The system of claim 1, wherein:
the sound generator is a headphone.
14. A system for treating tinnitus comprising:
a clinical controller executing tinnitus therapy software;
a vagus nerve stimulation (VNS) implantable pulse gen-
erator (IPG) in communication with theclinical control-
ler and receiving stimulation signals from the clinical
controller;
a VNSlead connected to the VNS IPG;
a VNSelectrode connected to the VNS lead and receiving
stimulation signals through the VNSlead from theVNS
IPG; and
a sound generator connected to the clinical controller,
whereinthe clinical controller plays selected soundfiles
through the sound generator while sending stimulation
signals to the VNS IPG such that respective selected
sounds of respective sound files may be heard by a
patient while a stimulation pulse train at the VNS elec-
trode causes the patient’s vagus nerve to be stimulated,
wherein
the system is configured to receive input based on the
patient’s tinnitus frequency, and
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the selected soundsare therapeutic tones, and wherein the
system is configured to automatically play the therapeu-
tic tones such that they are at least a half-octave below
the patient’s tinnitus frequency.
15. The system ofclaim 14, wherein theclinical controller
is a laptop computer.
16. The system ofclaim 14, wherein the VNS IPGreceives
stimulation parameters from the clinical controller.
17. The system of claim 14, wherein the selected sounds
are therapeutic tones, and wherein the system is configured to
execute a session that automatically applies at least 100 thera-
peutic tones per day.
18. The system of claim 14, wherein the selected sounds
are therapeutic tones, and wherein the system is configured to
execute a session that automatically applies at least 300 thera-
peutic tones per day.
19. The system of claim 14, wherein the selected sounds
are therapeutic tones, and wherein the system is configured to
play each therapeutic tone such that each therapeutic tone has
a duration of about 500 milliseconds.
20. The system of claim 14, wherein the selected sounds
are therapeutic tones, and wherein the system is configured to
execute a session that repetitively plays each of the plurality
of therapeutic tones in a temporally random manner.
21. The system of claim 14, wherein the selected sounds
are therapeutic tones, and wherein the system is configured to
execute a session that repetitively plays each of the plurality
of therapeutic tones in a frequency-based random manner.
22. The system of claim 14, wherein the selected sounds
are therapeutic tones, and wherein the system is configured to
execute a session that plays each therapeutic tone such that it
is a pure tone.
23. The system of claim 14, wherein the selected sounds
are therapeutic tones, and wherein the system is configured to
shape the therapeutic tones with a ramp function.
24. The system of claim 14, wherein the selected sounds
are therapeutic tones, and wherein the system is configured to
encode the therapeutic tones with location data.
25. The system of claim 14, wherein the selected sounds
are therapeutic tones, and wherein the system is configured to
automatically play the therapeutic tones such that they are at
least a half-octave above the patient’s tinnitus frequency.
26. The system of claim 14, wherein:
the sound generator is a headphone.
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